

NITROGEN BRIDGEHEAD COMPOUNDS PART 14¹. ACYLATION OF ETHYL 6-METHYL-4-OXO-6,7,8,9-TETRAHYDRO-PYRIDO(1,2-a)PYRIMIDINE-3-CARBOXILATE WITH ISOCYANATES


Bitter István^{*a}, Hermeicz István^{*}, Tóth Gábor^b, Dvortsák Péter,
 Bende Zoltán^a and Mészáros Zoltán

a/ CHINOIN Pharm. and Chem. Works, H-1325 Budapest, P.O.Box 110, Hungary
 b/ Technical University; Department of Organic Chemical Technology and
 NMR Laboratory of the Institute for General and Analytical Chemistry,
 H-1111 Budapest, Gellért tér 4. Hungary.

The 9-carbamoyl derivatives /3-9/ can be prepared from title compound /1/ with isocyanates /2/. 3-9 are mixtures of the cis /Z/ and trans /E/ imines and the enamine /e/. The equilibrium depends on the substituents R,X and on the solvent.

In the course of our pharmaceutical research work² we aimed to prepare new 6,7,8,9-tetrahydro-pyrido(1,2-a)pyrimidine derivatives by introducing different syn-thonones into the reactive 9-position³ of the ring. We have previously reported the reaction of the title compound /1/ with iminium chlorides⁴.

Now we describe the reaction of 1 with isocyanates /2a-e/ and isothiocyanates /2f,g/ which are known to react with CH acidic compounds⁵.




The aryl isocyanates /2a-e/ reacted with 1 at 80-90°C in 4-6 hrs /molar ratio 1:1,1/. The products crystallized on treating with EtOH /see Table 1/. Under similar conditions the alkyl isocyanates and isothiocyanates did not show reaction, even in the presence of tertiary amine catalyst. Using sodium hydride /in anhydrous benzene under argon atmosphere/, to generate the carbanion from the pyridopyrimidine, the isothiocyanates /2f,g/ readily reacted with 1, /at 25°C, in 2 hrs/ and yielded the 9-thiocarbamoyl derivatives 8,9. The sodium salts of 8,9 were precipitated from the reaction mixture with ether, and treated with AcOH.

Table 1.

Isocyanates	Product	R	X	Yield %	mp. °C
2a	3	Ph	O	72	198-9 ^a
2b	4	3-Cl-Ph	O	70	193-5 ^a
2c	5	4-Cl-Ph	O	81	206-8 ^a
2d	6	3,4-Cl ₂ -Ph	O	78	208-9 ^a
2e	7	4-Me-C ₆ H ₅ -SO ₂	O	72	178-9 ^b
2f	8	Ph	S	56	173-5 ^b
2g	9	Me	S	52	200-1 ^a

recryst. from a/ EtOH; b/ MeCN.

The products 3-9 may exist in three forms: imine /cis and trans/ and enamine



form. Recently some examples have been reported⁶ for the imine-enamine tautomerism of tetrahydro-pyridopyrimidines. No report however is to be found on the isomeric Z and E imines. The ¹H-NMR spectra of 3, 8 and 9 /in CDCl₃ and in DMSO-d₆/ exhibit signals showing the presence of each of the above three tautomeric-isomeric forms. In CDCl₃ the enamine /stabilized by intramolecular hydrogen bonding/ is the predominant form, while in DMSO-d₆ the imines /Z and E/ predominate. In each form /Z,E,e/ the 6-methyl group is quasi-axial, due to A/1-3/ type allylic strain^{6c,7}. Characteristic chemical shifts in DMSO-d₆ and isomeric ratios are presented in Table 2. ¹H-NMR signals of the isomeric imines do not allow structural assignment /to the cis or trans imine forms/. We carry on further study for correct assignment.

Table 2. ¹H-NMR chemical shifts; δ ppm; /Intensity/ in DMSO-d₆ Brucker WM-250

Com-pound	2-H	6-H	7-and 8-CH ₂	6-Me	1-NH	NH-CO	9-H	R	OCH ₂ CH ₃	Ratio in DMSO	Ratio in CDCl ₃
<u>3e</u>	8,31d /O,4H/				13,86d /O,4H/	8,86s /O,4H/	-	Ph	4,14q	40	92
<u>3E</u> or <u>3Z</u>	8,32s /O,4H/	4,88m /1H/	1,55-2,80m /4H/	1,09d /2,4H/	-	10,42s /O,4H/	4,1- 4,4 ^a	7,00- 7,40 /3H/	4,23q	40	8
	8,46s /O,2H/			1,36d /O,6H/	-	10,36s /O,2H/		7,55- 7,65 /2H/	1,23t 1,26t	20	
<u>8e</u>	^b			1,25 ^c /?	15,85d /O,25H/	9,82s /O,25H/	-	Ph	4,17q	25	75
<u>8E</u> or <u>8Z</u>	8,48s	4,84m /O,55H/	1,60-2,80m /4H/	1,47d /1,65H/	-	12,09s /O,55H/	4,1- 4,3 ^a	7,20- 7,55 /3H/	4,25q	55	8
	8,46s	4,94m /O,45H/		1,14d /O,6H/	-	11,93s /O,2H/	4,67m /O,2H/	7,75- 8,00 /2H/	1,24t 1,26t	20	17
<u>9e</u>										0	70
<u>9E</u> or <u>9Z</u>	8,43s /1H/	4,80m /O,7H/	1,70-2,60m /4H/	1,43d /2,1H/	-	10,60m /O,7H/	4,1- 4,3 ^a	Me	4,16q	70	20
		4,92m /O,3H/		1,07d /O,9H/	-	10,38m /O,3H/	4,37m /O,3H/	3,02 /3H/	4,24q 1,22t 1,26t	30	10

a/ overlap with OCH₂; b/ overlap with Ph /7,75-8,00/; c/ overlap with OCH₂-CH₃.

REFERENCES: 1./ Part 13: I. Hermezc and Z. Mészáros: Heterocycles in press; 2./ J. Knoll et al.: *Arzneim.Forsch. /Drug Res./* 1971, 21, 719; b./ J. Knoll et al.: *ibid.* 1979, 29, 766; c./ I. Hermezc et al.: *ibid.* in press; d./ Z. Mészáros: *Kémiai Közlemények* 1978, 50, 173, *Chem. Abstr.* 89, 156.994a; e./ F. Fülöp et al.: *J. Heterocyclic Chem.* 1979, 16, 457; 3a./ Z. Mészáros et al.: *Arzneim.Forsch. /Drug Res./* 1972, 22, 815; b./ G. Náráy-Szabó et al.: *J.C.S. Perkin I* 1974, 1753; 4./ I. Hermezc et al.: *Tetrahedron Lett.* 1979, 2557; 5./ S. Petersen: *Ann.* 1949, 562, 205; 6a./ H.L. Yale and E.R. Spitzmiller: *J. Heterocyclic Chem.* 1976, 13, 797; b./ H. Wamhoff and L. Lichtenthäler: *Chem. Ber.* 1978, 111, 2813; c./ I. Hermezc et al.: *Tetrahedron Lett.* 1979, 1337; 7a./ F. Johnson: *Chem. Rev.* 1968, 68, 375; b./ K. Nagarajan et al.: *Helv. Chim. Acta* 1978, 61, 1246; c./ G. Tóth et al.: *J. Heterocyclic Chem.* in press.